Achilles Therapeutics Reports Q3 2024 Financial Results

Written by Emily J. Thompson, Senior Investment Analyst

ACHL%

Source: Business Insider

Updated: Nov 29 2024

0mins

Source: Business Insider

Q3 Earnings Report: Achilles Therapeutics Plc reported a cash position of $86.1 million as of September 30, with a net loss of $19.6 million for the quarter, reflecting increased R&D expenses and a strategic shift away from its TIL-based cNeT program.
Future Strategies: The company is exploring new strategic options with BofA Securities to enhance shareholder value and continue targeting clonal neoantigens despite recent financial losses.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Achilles Therapeutics Reports Q3 2024 Financial Results

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Pictet North America Advisors Buys 2,703 Shares of MercadoLibre (MELI) for $5.68 Million

Louisbourg Investments Sells 73,600 Shares of OR Royalties for Approximately $2.58 Million

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch